Human papillomavirus vaccines: An update for gynecologists

Clinical Obstetrics and Gynecology

Volumn 51, Issue 3, 2008, Pages 527-532

  Ault, Kevin A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical dysplasia; HPV; Vaccination

Indexed keywords

PLACEBO; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GYNECOLOGY; HUMAN; PRACTICE GUIDELINE; PREVALENCE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; WART VIRUS; FEMALE; IMMUNOLOGY; REVIEW; SEXUALLY TRANSMITTED DISEASE; STANDARD; UTERINE CERVIX TUMOR; VACCINATION; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 54449100181     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31818092df     Document Type: Article

References (13)

1. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis. 2008;197:279-282.
2. Dunne E, Unger E, Sternberg M, et al. Prevalence of HPV infection among females inthe United States. JAMA. 2007; 297:813-819.
3. Castle PE, Wacholder S, Sherman M, et al. Absolute risk of asubsequent abnormal pap among oncogenic human papilomavirus DNA-positive, cytologically negative women. Cancer. 2002;95: 2145-2151.
4. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical pre-cancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079.
5. Mao C, Hughes JP, Kiviat N, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol. 2003;188:677-684.
6. Ault KA. Virus-like particles as a potential vaccine for human papillomavirus. Papillomavirus Rep. 2003;14:47-51.
7. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
8. Koutsky L, FUTURE II Study Group. Efficacy and safety of a prophylactic quadrivalent human papillomavirus (types 6/11/16/18) L1 virus-like-particle vaccine in the prevention of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a randomized controlled trial. N Engl J Med. 2007; 356:1915-1927.
9. Suzanne M, Garland MD, Mauricio Hernandez-Avila MD, et al. A quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEJM. 2007; 356:1928-1943.
10. Rambout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007;177: 469-479.
11. CDC. quadrivalent human papillomavirus vaccine. MMWR. 2007;56:1-24.
12. Presentation available at: http://www. cdc.gov/vaccines/recs/acip/ downloads/mtg-slides-jun07/35-hpv3-iskander.pdf. Assessed on May 12, 2008.
13. Paavonen J, Jenkins D, Bosch X, et al. Efficacy of a prophylactic adjuvant bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170.